Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children

Augmented renal clearance (ARC) is characterized by enhanced renal clearance, which leads to insufficient vancomycin exposure and treatment failure. In haematologic malignancy patients, determination of optimal vancomycin dosage is essential because of high stake of life‐threatening bacterial infection and increased clearance. The aim of this study was to describe vancomycin pharmacokinetic parameters in haematologic malignancy with augmented renal clearance children and define the appropriate dosing regimen to achieve an AUC0‐24h/MIC ≥400.

[1]  Vancomycin , 2019, Reactions Weekly.

[2]  M. Imai,et al.  Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients. , 2019, Biological & pharmaceutical bulletin.

[3]  A. Cook,et al.  Augmented Renal Clearance , 2019, Pharmacotherapy.

[4]  Baosen Zhou,et al.  Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. , 2019, Journal of infection and public health.

[5]  A. Isla,et al.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review , 2018, Clinical Pharmacokinetics.

[6]  J. Le,et al.  Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients* , 2017, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[7]  Geisa Cristina Silva Alves,et al.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis , 2017, European Journal of Clinical Pharmacology.

[8]  S. Zhai,et al.  Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. , 2016, The Journal of antimicrobial chemotherapy.

[9]  N. André,et al.  Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization , 2016, Therapeutic drug monitoring.

[10]  K. Itoh,et al.  Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance , 2016, Therapeutic drug monitoring.

[11]  J. Roberts,et al.  Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. , 2015, Current opinion in pharmacology.

[12]  J. D. De Waele,et al.  Augmented renal clearance and therapeutic monitoring of β-lactams. , 2015, International journal of antimicrobial agents.

[13]  J. Roberts,et al.  Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds , 2014, Critical Care.

[14]  Y. Keynan,et al.  Vancomycin Revisited – 60 Years Later , 2014, Front. Public Health.

[15]  A. Baruchel,et al.  Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease , 2014, Antimicrobial Agents and Chemotherapy.

[16]  A. Dubin,et al.  Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment , 2014, Revista Brasileira de terapia intensiva.

[17]  V. Briedis,et al.  Augmented renal clearance – an evolving risk factor to consider during the treatment with vancomycin , 2013, Journal of clinical pharmacy and therapeutics.

[18]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[19]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[20]  Ryo Matsushita,et al.  Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma. , 2012, Anticancer research.

[21]  B. Bruguerolle,et al.  Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.

[22]  J. Roberts,et al.  Implications of augmented renal clearance in critically ill patients , 2011, Nature Reviews Nephrology.

[23]  Y. Bertrand,et al.  Vancomycine : quelles doses pour une meilleure efficacité en hémato-oncologie pédiatrique ? , 2011 .

[24]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  B. Charles,et al.  Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination , 2010, Antimicrobial Agents and Chemotherapy.

[26]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[28]  E. Niclas Jonsson,et al.  Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..

[29]  M. J. García,et al.  Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies , 2005, Antimicrobial Agents and Chemotherapy.

[30]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[31]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[32]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[33]  A. Brugarolas,et al.  Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. , 2000, Therapeutic drug monitoring.

[34]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.